Delivery of immunogenic molecules vis HBsAg particles
AssigneesYissum Research Development Company of the Hebrew University of Jerusalem, Jorg Reimann
InventorsJörg Reimann, Yechezkel Barenholz, Dvorah Diminsky, Reinhold Schirmbeck
Life of this patent
Estimating the term…
Abstract
Compositions of HBsAg particles having biologically active molecules contained in the particles, and methods of their use, e.g. in stimulating enhanced immune responses, are described. Antigenic peptides contained in HBsAg particles were found to produce a CTL response where none was elicited by the peptide alone. Encapsulation of immunostimulating molecules, such as cytokines, greatly enhanced the CTL response evoked by the HBsAg particles themselves.
Claims22
A method of stimulating or enhancing a CTL response to a biologically active molecule in a mammalian subject in need of such CTL response stimulation and enhancement, comprising administering to said subject by injection into the body of said subject, in a manner so as to elicit a CTL response, an effective amount of a composition comprising the biologically active molecule, either entrapped within the interior of an HBsAg particle or exposed or present at the surface of an HBsAg particle by incubating said HBsAg particle at a temperature of about 35° C. to about 60° C. in an aqueous medium in the presence of the biologically active molecule, wherein said biologically active molecule is not covalently attached to said HBsAg particle, and wherein said CTL response is enhanced relative to that produced by the biologically active molecule alone.
A composition comprising an HBsAg particle, a biologically active molecule either entrapped within the interior of an HBsAg particle or exposed or present at the surface of an HBsAg particle, and in addition to the biologically active molecule an immunostimulating molecule either entrapped within the interior of said HBsAg particle or exposed or present at the surface of said HBsAg particle, wherein said biologically active molecule is not covalently attached to said HBsAg particle.
A method of incorporating a biologically active molecule into an HBsAg particle, comprising a step of incubating said particle at a temperature of about 35° C. to about 60° C. in an aqueous medium in the presence of said molecule.
Dependencies are inferred from the claim text.